flow semaglutide clinical trial Effects of with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the Get With the FLOW! in:

Yeah, so this is the big question and this is the point of real concern from my perspective

"Alaska Adds 18 New Routes"

A more recent study published in December 2023 found a similar result in FDA-approved tirzepatide, the main ingredient in Mounjaro and Zepbound

Some approximate equivalencies have emerged from clinical observation, though these should guide rather than dictate dosing decisions

Individual safety findings for one molecule dont necessarily predict class-wide effects, says Finer, safety signals often relate to specific structural features or off-target activities rather than the primary mechanism of action. He thinks oral GLP-1 drugs have the potential for better dose titration, which might help control the current, mainly gastrointestinal, side-effects of the injectable peptides